Completed lung cancer projects
Completed lung cancer projects
THORA
A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer (THORA)
170 eligible patients from 22 Scandinavian hospitals were recruited to the trial, and randomized to standard chemoradiotherapy with twice-daily fractions of 45Gy versus high-dose radiotherapy of 60Gy. Results showed a significant improval in survival for patients in the high-dose arm, without adding toxicity. Twice-daila thoracic radiotherapy of 60Gy is thus an attractive alternative to lower-dose treatment regimes.
IDA
A Randomized Phase III Study Comparing Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer
105 patients were randomized to immediate switch-maintenance pemetrexed therapy with pemetrexed at progression. There were no significant differences in toxicity or HRQoL between the arms, and a trend towards prolonged overall survival and significantly longer progression-free survival from switch-maintenance pemetrexed therapy when 73% of patients in the control arm received pemetrexed at progression.
HAST
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
157 patients were included and treated with either chemotherapy and once daily thoracic radiotherapy (TRT) with 42 Gy (15 fractions) or chemotherapy and twice daily TRT with 45 Gy (30 fractions). No firm conclusions about efficacy could be drawn from the phase II trial, however the twice daily regimen resulted in a significant increase in complete responses and a numerically longer median overall survival. There was no difference in toxicity between the TRT regimes.